Deglycosylated ginsenosides are more potent inducers of CYP1A1, CYP1A2 AND CYP3A4 expression in HepG2 cells than glycosylated ginsenosides

Drug Metabolism and Pharmacokinetics

Volumn 26, Issue 2, 2011, Pages 201-205

  Hao, Miao ^a,b   Ba, Qian ^a,b   Yin, Jun ^a,b   Li, Jingquan ^a,b   Zhao, Yuqing ^c   Wang, Hui ^a,b  

^a Chinese Academy of Sciences   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Drug interactions; Ginseng; HepG2; Induction; P450

Indexed keywords

2 HYDROXYPROTOPANAXATRIOL; 20 DAMMARANE 3BETA,12BETA,20,25 TETROL; 20,25 METHOXYLDAMMARANE 3BETA,12BETA20 TRIOL; AGLYCONE; GINSENOSIDE; GINSENOSIDE RB 1; GINSENOSIDE RB 3; GINSENOSIDE RD; GINSENOSIDE RE; GINSENOSIDE RG 1; GINSENOSIDE RG 2; GINSENOSIDE RG 3; GINSENOSIDE RH 2; PROTOPANAXADIOL; SAPOGENIN; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; CYTOCHROME P450 1A1 GENE; CYTOCHROME P450 1A2 GENE; CYTOCHROME P450 3A4 GENE; DEGLYCOSYLATION; GENE; HUMAN; HUMAN CELL; INTESTINE FLORA; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; STRUCTURE ACTIVITY RELATION;

EID: 79955738030     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-10-NT-056     Document Type: Article

References (35)

1. Attele, A. S., Wu, J. A. and Yuan, C. S.: Ginseng pharmacology: multiple constituents and multiple actions. Biochem. Pharmacol., 58: 1685-1693 (1999).
2. Barnes, P.M., Bloom, B. and Nahin, R.L.: CDC National Health Statistics Report #12 (2008).
3. Helms, S.: Cancer prevention and therapeutics: Panax ginseng. Altern. Med. Rev., 9: 259-274 (2004).
4. Fughberman, A.: Herb-drug interactions. Lancet, 355: 134-138 (2000).
5. Coon, J. T. and Ernst, E.: Panax ginseng: a systematic review of adverse effects and drug interactions. Drug Saf., 25: 323-344 (2002).
6. Peter Guengerich, F.: Cytochrome P450: what have we learned and what are the future issues? Drug Metab. Rev., 36: 159-197 (2004).
7. Zhou, S., Gao, Y., Jiang, W., Huang, M., Xu, A. and Paxton, J. W.: Interactions of herbs with cytochrome P450. Drug Metab. Rev., 35: 35-98 (2003).
8. Delgoda, R. and Westlake, A. C.: Herbal interactions involving cytochrome p450 enzymes: a mini review. Toxicol. Rev., 23: 239-249 (2004).
9. Chang, T. K., Chen, J. and Benetton, S. A.: In vitro effect of standardized ginseng extracts and individual ginsenosides on the catalytic activity of human CYP1A1, CYP1A2, and CYP1B1. Drug Metab. Dispos., 30: 378-384 (2002).
10. He, N. and Edeki, T.: The inhibitory effects of herbal components on CYP2C9 and CYP3A4 catalytic activities in human liver microsomes. Am. J. Ther., 11: 206-212 (2004).
11. He, N., Xie, H. G., Collins, X., Edeki, T. and Yan, Z.: Effects of individual ginsenosides, ginkgolides and flavonoids on CYP2C19 and CYP2D6 activity in human liver microsomes. Clin. Exp. Pharmacol. Physiol., 33: 813-815 (2006).
12. Henderson, G. L., Harkey, M. R., Gershwin, M. E., Hackman, R. M., Stern, J. S. and Stresser, D. M.: Effects of ginseng components on c-DNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci., 65: PL209-PL214 (1999).
13. Wang, Y., Ye, X., Ma, Z., Liang, Q., Lu, B., Tan, H., Xiao, C., Zhang, B. and Gao, Y.: Induction of cytochrome P450 1A1 expression by ginsenoside Rg1 and Rb1 in HepG2 cells. Eur. J. Pharmacol., 601: 73-78 (2008).
14. Raucy, J. L.: Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products. Drug Metab. Dispos., 31: 533-539 (2003).
15. Gurley, B. J., Gardner, S. F., Hubbard, M. A., Williams, D. K., Gentry, W. B., Cui, Y. and Ang, C. Y.: Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin. Pharmacol. Ther., 72: 276-287 (2002).
16. Wang, R. W., Newton, D. J., Liu, N., Atkins, W. M. and Lu, A. Y.: Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent. Drug Metab. Dispos., 28: 360-366 (2000).
17. Harkey, M. R., Henderson, G. L., Gershwin, M. E., Stern, J. S. and Hackman, R. M.: Variability in commercial ginseng products: an analysis of 25 preparations. Am. J. Clin. Nutr., 73: 1101-1106 (2001).
18. Hao, M., Zhao, Y., Chen, P., Huang, H., Liu, H., Jiang, H., Zhang, R. and Wang, H.: Structure-activity relationship and substrate-dependent phenomena in effects of ginsenosides on activities of drug-metabolizing P450 enzymes. PLoS ONE, 3: e2697 (2008).
19. Westerink, W. M. and Schoonen, W. G.: Cytochrome P450 enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells. Toxicol. In Vitro, 21: 1581-1591 (2007).
20. Ma, Q. and Lu, A. Y.: CYP1A induction and human risk assessment: an evolving tale of in vitro and in vivo studies. Drug Metab. Dispos., 35: 1009-1016 (2007).
21. Anwar-Mohamed, A., Elbekai, R. H. and El-Kadi, A. O.: Regulation of CYP1A1 by heavy metals and consequences for drug metabolism. Expert Opin. Drug Metab. Toxicol., 5: 501-521 (2009).
22. Thummel, K. E. and Wilkinson, G. R.: In vitro and in vivo drug interactions involving human CYP3A. Annu. Rev. Pharmacol. Toxicol., 38: 389-430 (1998).
23. Nebert, D. W. and Russell, D. W.: Clinical importance of the cytochromes P450. Lancet, 360: 1155-1162 (2002).
24. Wang, W., Zhao, Y., Rayburn, E. R., Hill, D. L., Wang, H. and Zhang, R.: In vitro anti-cancer activity and structure-activity relationships of natural products isolated from fruits of Panax ginseng. Cancer Chemother. Pharmacol., 59: 589-601 (2007).
25. Wang, W., Rayburn, E. R., Hao, M., Zhao, Y., Hill, D. L., Zhang, R. and Wang, H.: Experimental therapy of prostate cancer with novel natural product anti-cancer ginsenosides. Prostate, 68: 809-819 (2008).
26. Wang, W., Wang, H., Rayburn, E. R., Zhao, Y., Hill, D. L. and Zhang, R.: 20(S)-25-methoxyl-dammarane-3beta, 12beta, 20-triol, a novel natural product for prostate cancer therapy: activity in vitro and in vivo and mechanisms of action. Br. J. Cancer, 98: 792-802 (2008).
27. Wang, W., Rayburn, E. R., Zhao, Y., Wang, H. and Zhang, R.: Novel ginsenosides 25-OH-PPD and 25-OCH3-PPD as experimental therapy for pancreatic cancer: anticancer activity and mechanisms of action. Cancer Lett., 278: 241-248 (2009).
28. Fuzzati, N.: Analysis methods of ginsenosides. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 812: 119-133 (2004).
29. Yang, L., Liu, Y. and Liu, C. X.: Metabolism and pharmacokinetics of ginsenosides. Asian J. Pharmacodyn. Pharmacokinet., 6: 103-120 (2006).
30. Xu, Q. F., Fang, X. L. and Chen, D. F.: Pharmacokinetics and bioavailability of ginsenoside Rb1 and Rg1 from Panax notoginseng in rats. J. Ethnopharmacol., 84: 187-192 (2003).
31. Zhang, X., Zhang, D., Xu, J., Gu, J. and Zhao, Y.: Determination of 25-OH-PPD in rat plasma by high-performance liquid chromatography-mass spectrometry and its application in rat pharmacokinetic studies. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 858: 65-70 (2007).
32. Hasegawa, H.: Proof of the mysterious efficacy of ginseng: basic and clinical trials: metabolic activation of ginsenoside: deglycosylation by intestinal bacteria and esterification with fatty acid. J. Pharmacol. Sci., 95: 153-157 (2004).
33. Liu, Y., Li, W., Li, P., Deng, M. C., Yang, S. L. and Yang, L.: The inhibitory effect of intestinal bacterial metabolite of ginsenosides on CYP3A activity. Biol. Pharm. Bull., 27: 1555-1560 (2004).
34. Liu, Y., Zhang, J. W., Li, W., Ma, H., Sun, J., Deng, M. C. and Yang, L.: Ginsenoside metabolites, rather than naturally occurring ginsenosides, lead to inhibition of human cytochrome P450 enzymes. Toxicol. Sci., 91: 356-364 (2006).
35. Robertson, P., DeCory, H. H., Madan, A. and Parkinson, A.: In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil. Drug Metab. Dispos., 28: 664-671 (2000).